NY-ESO-1-SPECIFIC TCR-ENGINEERED T CELL IMMUNOTHERAPY FOR TRIPLE NEGATIVE BREAST CANCER

$4,345,648FY2016Defense Health AgencyDOD

University Of Southern California, Los Angeles CA

Investigators